Streetbeat News

Price Targets

UNP

Barclays analyst Brandon Oglenski maintains an Overweight rating on Union Pacific (NYSE:UNP) and raises the price target from $230 to $285.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 27, 2023 | 12:27 pm

ORLY

Wedbush analyst Seth Basham maintains a Neutral rating on O'Reilly Automotive (NASDAQ:ORLY) and raises the price target from $920 to $940.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:27 pm

MHO

Wedbush analyst Jay McCanless has maintained an Outperform rating on M/I Homes (NYSE:MHO) and raised the price target from $108 to $116.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:25 pm

TMO

Barclays analyst Luke Sergott maintains an Overweight rating on Thermo Fisher Scientific (NYSE:TMO) and raises the price target from $590 to $625.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 27, 2023 | 12:25 pm

CROX

Wedbush analyst Tom Nikic has reiterated an Outperform rating on Crocs (NASDAQ:CROX) and maintained a price target of $153.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:24 pm

TMHC

Barclays analyst Matthew Bouley maintains an Equal-Weight rating on Taylor Morrison Home (NYSE:TMHC) and raises the price target from $52 to $55.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 27, 2023 | 12:23 pm

KO

Wedbush analyst Gerald Pascarelli has maintained an Outperform rating on Coca-Cola (NYSE:KO) and raised the price target from $70 to $71.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:23 pm

CCS

Wedbush analyst Jay McCanless has reiterated an Outperform rating on Century Communities (NYSE:CCS) and maintained a price target of $89.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:22 pm

NOW

Barclays analyst Raimo Lenschow has maintained an Overweight rating on ServiceNow (NYSE:NOW) but lowered the price target from $646 to $644.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 27, 2023 | 12:22 pm

IMUX

Wedbush analyst Andreas Argyrides has reiterated his 'Outperform' rating on Immunic (NASDAQ:IMUX) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:21 pm